Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia

Journal of Clinical Lipidology

Volumn 3, Issue 5, 2009, Pages 332-340

  Davidson, Michael H ^a,b   Maki, Kevin C ^c   Bays, Harold ^d   Carter, Roderick ^e   Ballantyne, Christie M ^f  

^a RADIANT RESEARCH   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c Provident Clinical Research   (United States)

^d LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^e GLAXOSMITHKLINE   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

High density lipoprotein; Hypertriglyceridemia; Low density lipoprotein; Prescription omega 3 acid ethyl esters; Simvastatin

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN A2; APOLIPOPROTEIN C3; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; OMEGA 3 FATTY ACID; PLACEBO; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARTICLE SIZE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 70349742488     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2009.08.001     Document Type: Article

References (43)

1. Ginsberg H.N. Hypertriglyceridemia: new insights and new approaches to pharmacologic therapy. Am J Cardiol 87 (2001) 1174-1180
2. Eberly L.E., Stamler J., Neaton J.D., and Multiple Risk Factor Intervention Trial Research Group. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med 163 (2003) 1077-1083
3. Liu J., Sempos C.T., Donahue R.P., Dorn J., Trevisan M., and Grundy S.M. Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am J Cardiol 98 (2006) 1363-1368
4. Davidson M.H., Maki K.C., Pearson T.A., et al. Results of the National Cholesterol Education Program (NCEP) Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol 96 (2005) 556-563
5. Maki K.C. Dietary factors in the prevention of diabetes mellitus and coronary artery disease associated with the metabolic syndrome. Am J Cardiol 93 suppl 11A (2004) 12C-17C
6. Ginsberg H.N., Zhang Y.L., and Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res 36 (2005) 232-240
7. Mann D., Reynolds K., Smith D., and Muntner P. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother 42 (2008) 1208-1215
8. Harris W.S. N-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 65 suppl 5 (1997) 1645S-1654S
9. Lovaza® (omega-3-acid ethyl esters) [prescribing information] (2008), GlaxoSmithKline, Research Triangle Park, NC
10. Davidson M.H., Stein E.A., Bays H.E., et al. COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 29 (2007) 1354-1367
11. Otvos J.D., Collins D., Freedman D.S., et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorable changes by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 113 (2006) 1556-1563
12. Caslake M.J., Packard C.J., Suckling K.E., Holmes S.D., Chamberlain P., and Macphee C.H. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 150 (2000) 413-419
13. Contois J., McNamara J.R., Lammi-Keefe C.J., Wilson P.W., Massov T., and Schaefer E.J. Reference intervals for plasma apolipoprotein A-1 determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. Clin Chem 42 (1996) 507-514
14. Sacks F.M., Alaupovic P., Moye L.A., et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 102 (2000) 1886-1892
15. Nakajima K., Saito T., Tamura A., et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-11 and anti apo A-I immunoaffinity mixed gels. Clin Chim Acta 223 (1993) 53-71
16. Davidson M.H., Bays H.E., Stein E., Maki K.C., Shalwitz R.A., Doyle R., and TRIMS Investigators. Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects. Clin Cardiol 29 (2006) 268-273
17. Maki K.C., McKenney J.M., Reeves M.S., Lubin B.C., and Dicklin M.R. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. Am J Cardiol 102 (2008) 429-433
18. Cromwell W.C., Otvos J.D., Keyes M.J., et al. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study-Implications for LDL management. J Clin Lipidol 1 (2007) 583-592
19. Hsia J., Otvos J.D., Rossouw J.E., et al., Women's Health Initiative Research Group. Lipoprotein particle concentrations may explain the absence of coronary protection in the women's health initiative hormone trials. Arterioscler Thromb Vasc Biol 28 (2008) 1666-1671
20. El Harchaoui K., van der Steeg W.A., Stroes E.S., et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 6 49 (2007) 547-553
21. Huff M.W., and Telford D.E. Dietary fish oil increases conversion of very low density lipoprotein apoprotein B to low density lipoprotein. Arteriosclerosis 9 (1989) 58-66
22. Calabresi L., Donati D., Pazzucconi F., Sirtori C., and Franceschini G. Omacor in familial combined hyperlipidemia: effects on lipids and low-density lipoprotein subclasses. Atherosclerosis 148 (2000) 387-396
23. Chan D.C., Watts G.F., Barrett P.H., Beilin L.J., Redgrave T.G., and Mori T.A. Regulatory effects of HMG CoA reductase inhibitors and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Diabetes 51 (2002) 2377-2386
24. Chan D.C., Watts G.F., Mori T.A., Barrett H.R., Redgrave T.G., and Beilin L.J. Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity. Am J Clin Nutr 77 (2003) 300-307
25. Bucher H., Hengstler P., Schindler C., and Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 112 (2002) 298-304
26. Dagnelie P.C., Rietveld T., Swart G.R., Stijinen T., and van den Berg J.W. Effect of dietary fish oil on blood levels of free fatty acids, ketone bodies, and triacylglyercol in humans. Lipids 29 (1994) 41-45
27. Inagaki M., and Harris W.S. Changes in lipoprotein concentration in hypertriglyceridemic patients taking cholesterol-free fish oil supplements. Atherosclerosis 82 (1990) 237-246
28. Westphal S., Orth M., Ambrosch A., Osmundsen K., and Luley C. Postprandial chylomicrons and VLDLs in severe hypertriacylglycerolemia are lowered more effectively than chylomicron remnants after treatment with n-3 fatty acids. Am J Clin Nutr 71 (2000) 914-920
29. Chan D.C., Nguyen M.N., Watts G.F., and Barrett P.H. Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism. J Clin Endocrinol Metab 93 (2008) 557-564
30. Kawakami A., Osaka M., Tani M., et al. Apolipoprotein CIII links hyperlipidemia with vascular endothelial cell dysfunction. Circulation 118 (2008) 731-741
31. Harris W.S., Lu G., Rambjør G.S., et al. Influence of n-3 fatty acid supplementation on the endogenous activities of plasma lipases. Am J Clin Nutr 66 (1997) 254-260
32. Packard C.J. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans 31 (2003) 1066-1069
33. Packard C.J., Demant T., Stewart J.P., et al. Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. J Lipid Res 41 (2000) 305-317
34. Nozaki S., Matsuzawa Y., Hirano K., Sakai N., Kubo M., and Tarui S. Effects of purified eicosapentaenoic acid ethyl ester on plasma lipoproteins in primary hypercholesterolemia. Int J Vitam Nutr Res 62 (1992) 256-260
35. Anderson J.L. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention. Am J Cardiol 101 (2008) 23F-33F
36. Sudhir K. Lipoprotein-associated phospholipase A2, vascular inflammation and cardiovascular risk prediction. Vasc Health Risk Manag 2 (2006) 153-156
37. Koenig W., Khuseyinova N., Lowel H., Trischler G., and Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 110 (2004) 1903-1908
38. Gazi I., Lourida E.S., Filippatos T., Tsimihodimos V., Elisaf M., and Tselepis A.D. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 51 (2005) 2264-2273
39. Gaubatz J.W., Gillard B.K., Massey J.B., et al. Dynamics of dense, electronegative low density lipoproteins and their preferential association with lipoprotein phospholipase A(2). J Lipid Res 48 (2007) 348-357
40. Burr M.L., Fehily A.M., Gilbert J.F., et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 30 (1989) 757-761
41. Marchioli R., Schweiger C., Tavazzi L., and Valagussa F. Efficacy of n-3 polyunsaturated fatty acids after myocardial infarction: results of GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Lipids 36 suppl (2001) S119-S126
42. GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet 372 (2008) 1223-1230
43. Yokoyama M., Origasa H., Matsuzaki M., et al., Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded endpoint analysis. Lancet 369 (2007) 1090-1098